%0 Journal Article %A Mainak Das Gupta %A Yannick Flaskamp %A Robin Roentgen %A Hannes Juergens %A Jorge Armero Gimenez %A Frank Albrecht %A Johannes Hemmerich %A Zulfaquar Ahmad Arfi %A Jakob Neuser %A Holger Spiegel %A Alexei Yeliseev %A Lusheng Song %A Ji Qiu %A Charles Williams %A Ricarda Finnern %T ALiCE®: A versatile, high yielding and scalable eukaryotic cell-free protein synthesis (CFPS) system %D 2022 %R 10.1101/2022.11.10.515920 %J bioRxiv %P 2022.11.10.515920 %X Eukaryotic cell-free protein synthesis (CFPS) systems have the potential to simplify and speed up the expression and high-throughput analysis of complex proteins with functionally relevant post-translational modifications (PTMs). However, low yields and the inability to scale such systems have so far prevented their widespread adoption in protein research and manufacturing.Here, we present a detailed demonstration for the capabilities of a CFPS system derived from Nicotiana tabacum BY-2 cell culture (BY-2 lysate; BYL). BYL is able to express diverse, functional proteins at high yields in under 48 hours, complete with native disulfide bonds and N-glycosylation. An optimised version of the technology is commercialised as ‘ALiCE®’, engineered for high yields of up to 3 mg/mL. Recent advances in the scaling of BYL production methodologies have allowed scaling of the CFPS reaction. We show simple, linear scale-up of batch mode reporter proten expression from a 100 μL microtiter plate format to 10 mL and 100 mL volumes in standard Erlenmeyer flasks, culminating in preliminary data from 1 L reactions in a CELL-tainer® CT20 rocking motion bioreactor. As such, these works represent the first published example of a eukaryotic CFPS reaction scaled past the 10 mL level by several orders of magnitude.We show the ability of BYL to produce the simple reporter protein eYFP and large, multimeric virus-like particles directly in the cytosolic fraction. Complex proteins are processed using the native microsomes of BYL and functional expression of multiple classes of complex, difficult-to-express proteins is demonstrated, specifically: a dimeric, glycoprotein enzyme, glucose oxidase; the monoclonal antibody adalimumab; the SARS-Cov-2 receptor-binding domain; human epidermal growth factor; and a G protein-coupled receptor membrane protein, cannabinoid receptor type 2. Functional binding and activity are shown using a combination of surface plasmon resonance techniques, a serology-based ELISA method and a G protein activation assay. Finally, in-depth post-translational modification (PTM) characterisation of purified proteins through disulfide bond and N-glycan analysis is also revealed - previously difficult in the eukaryotic CFPS space due to limitations in reaction volumes and yields.Taken together, BYL provides a real opportunity for screening of complex proteins at the microscale with subsequent amplification to manufacturing-ready levels using off-the-shelf protocols. This end-to-end platform suggests the potential to significantly reduce cost and the time-to-market for high value proteins and biologics.Competing Interest StatementMDG, YF, RR, HJ, JAG, FA, JH, ZAA, JN, CW and RF were employed by LenioBio GmbH at the time of their contributions. RF is also a stakeholder in the company. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. %U https://www.biorxiv.org/content/biorxiv/early/2022/11/10/2022.11.10.515920.full.pdf